Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB

Table 1

Clinicopathological characteristics of stage IV NSCLC patients.

Characteristics ()		(%)
Age
Median		66
Range		47-80
<70 y		57 (67.1)
≥70 y		28 (32.9)
Sex
Male		62 (72.9)
Female		23 (27.1)
Smoking
Current/former		39 (45.9)
No		46 (54.1)
EOCG
0-1		66 (88.2)
2		19 (11.8)
Stage
IVA		38 (44.7)
IVB		47 (55.3)
Pathology
LUSC		37 (43.5)
LUAD		48 (56.5)
Biopsy site
Primary lung tumor		53 (62.4)
Lymph nodes		19 (22.4)
Liver		2 (2.4)
Pleural/pericardial effusion		6 (7.1)
Subcutaneous nodules		2 (2.4)
Bone and surrounding soft tissue		3 (3.5)
Biopsy method
Bronchoscope		29 (34.1)
EBUS-TBNA		5 (5.9)
Computed tomography/Doppler ultrasound		37 (43.6)
Pleural/pericardial puncture		7 (8.2)
Lymph node resection		7 (8.2)
T
T1-2		39 (25.8)
T3-4		46 (54.2)
N
N1		7 (8.2)
N2		15 (17.6)
N3		63 (74.1)
M
M1a		30 (35.3)
M1b		9 (10.6)
M1c		46 (54.1)
Metastatic site
Liver
Yes		7 (8.2)
No		78 (91.8)
Bone
Yes		42 (49.4)
No		43 (50.6)
Brain
Yes		7 (8.2)
No		78 (91.8)
Pleural/lung
Yes		44 (51.8)
No		41 (48.2)
Other sites
Yes		50 (58.8)
No		35 (41.2)
EGFR
Wild		75 (88.2)
Mutant		10 (11.8)
PD-L1(22C3)
<1%		7 (8.2)
1-49%		11 (12.9)
≥50%		19 (22.4)
Unknown		48 (56.5)
Line of treatment
1st		32 (37.6)
2nd		39 (45.9)
≥3		14 (16.5)
Treatment regimen
Mono drug anti-PD1		30 (35.3)
Anti-PD1+chemotherapy		49 (57.6)
Anti-PD1+chemotherapy+antiangiogenesis		6 (7.1)
Radiation therapy	Yes	18 (21.2)
	No	67 (78.8)
NLR	Median (mean)	4.39 (5.78)
	Range	0.89-24.28
dNLR	Median (mean)	2.9 (3.3)
	Range	0.72-12.75
LDH	Median (mean)	219 (233.68)
	Range	23-816
LMR	Median (mean)	2.71 (3.07)
	Range	0.44-10.0
ALB	Median (mean)	40.5 (38.95)
	Range	20.3-48.9
PAB	Median (mean)	19.3 (20.17)
	Range	2.6-47